Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tebipenem pivoxil - Spero Therapeutics

Drug Profile

Tebipenem pivoxil - Spero Therapeutics

Alternative Names: GSK-3778712; L-084; ME1211; Orapenem; SPR-994; TBP-PI-HBr; TBPM-PI-HBr; Tebipenem; Tebipenem HBr; Tebipenem pivoxil hydrobromide; Tebipenem-prodrug

Latest Information Update: 10 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth K.K.
  • Developer GSK; Meiji Seika Pharma; Spero Therapeutics; Wyeth K.K.
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Azabicyclo compounds; Azetidines; Carbapenems; Esters; Small molecules; Thiazoles
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilus infections; Streptococcal infections
  • Preregistration Pyelonephritis; Urinary tract infections
  • Phase II Shigella infections
  • No development reported Unspecified

Most Recent Events

  • 02 Jan 2024 Phase-III clinical trials in Pyelonephritis in Bosnia-Herzegovina (PO) (NCT06059846) (EudraCT2023-503785-22-00)
  • 02 Jan 2024 Phase-III clinical trials in Urinary tract infections (Complicated) in Bosnia-Herzegovina (PO) (NCT06059846) (EudraCT2023-503785-22-00)
  • 02 Jan 2024 Spero Therapeutics initiates enrolment in the phase-III PIVOT-PO trial for Urinary tract infections (Complicated) and Pyelonephritis in Bosnia-Herzegovina, Bulgaria, Croatia, Georgia, Hungary, Moldova, Multinational, Poland, Romania, Serbia, Slovakia, South Africa, USA (PO) (NCT06059846)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top